These findings indicate that combined inhibition of both Cnr1 and Cnr2 receptors could be of value in the prevention of age‐related bone loss due to their inhibitory effects on osteoclast number, although it remains to be seen whether this strategy would have clinical utility given the many other osteoclast inhibitors that are currently available for clinical use. The gene discussed is CNR1; the disease is age.